Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-126 open-label extension in mild-to-moderate Alzheimer's disease
2012-000537-39Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nelonicline in Alzheimer's disease (AD), sponsored by AbbVie Inc. Primary endpoint: Long-term safety and tolerability. Started Jun 2012; status: terminated.
02
Drugs
nelonicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2012-000537-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000537-39.